Mizutani Kazuki, Nakazawa Gaku, Yamaguchi Tomohiro, Ogawa Mana, Okai Tsukasa, Yashima Fumiaki, Naganuma Toru, Yamanaka Futoshi, Tada Norio, Takagi Kensuke, Yamawaki Masahiro, Ueno Hiroshi, Tabata Minoru, Shirai Shinichi, Watanabe Yusuke, Yamamoto Masanori, Hayashida Kentaro
Division of Cardiology, Department of Medicine, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511, Japan.
Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Eur Heart J Open. 2021 Nov 15;1(3):oeab036. doi: 10.1093/ehjopen/oeab036. eCollection 2021 Nov.
To investigate the ability of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and ARC-HBR score to predict 2-year bleeding and mortality in patients undergoing transcatheter aortic valve replacement (TAVR).
We enrolled 2514 patients who underwent successful TAVR during 2013-17. In this study, we used the ARC-HBR score for further HBR-risk stratification, and the ARC-HBR score was calculated as follows: each major criterion was 2 points and each minor criterion was 1 point. The impact of the ARC-HBR criteria and increasing ARC-HBR score on the incidence of moderate/severe bleeding events, mortality, and ischaemic stroke in the first 2 years were evaluated. We used survival classification and regression tree (CART) analysis for 2-year moderate or severe bleeding events, and patients were statistically classified into HBR low- (ARC-HBR score ≤1), intermediate- (ARC-HBR score = 2-4), or high-risk (ARC-HBR score ≥5) groups, and 91.4% were at HBR (ARC-HBR score ≥2). The rates of 2-year moderate/severe bleeding events and all-cause mortality were higher in the ARC-HBR group and highest in the HBR high-risk group. An increased HBR score was significantly associated with moderate/severe bleeding events [hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.07-1.31; = 0.001] and all-cause mortality (adjusted HR 1.24, 95% CI 1.17-1.32; < 0.001).
The ARC-HBR criteria identify patients at HBR after TAVR; an increased ARC-HBR score is associated with 2-year moderate/severe bleeding events and mortality.
研究学术研究联盟高出血风险(ARC-HBR)标准及ARC-HBR评分预测经导管主动脉瓣置换术(TAVR)患者2年出血及死亡情况的能力。
我们纳入了2013年至2017年间成功接受TAVR的2514例患者。在本研究中,我们使用ARC-HBR评分进行进一步的高出血风险分层,ARC-HBR评分计算如下:每个主要标准为2分,每个次要标准为1分。评估ARC-HBR标准及ARC-HBR评分升高对前2年中重度出血事件、死亡率和缺血性卒中发生率的影响。我们对2年中重度出血事件采用生存分类和回归树(CART)分析,患者在统计学上被分为低出血风险(ARC-HBR评分≤1)、中度出血风险(ARC-HBR评分=2-4)或高出血风险(ARC-HBR评分≥5)组,91.4%的患者处于高出血风险(ARC-HBR评分≥2)。ARC-HBR组2年中重度出血事件和全因死亡率较高,高出血风险组最高。出血风险评分升高与中重度出血事件显著相关[风险比(HR)1.19,95%置信区间(CI)1.07-1.31;P=0.001]和全因死亡率(校正后HR 1.24,95%CI 1.17-1.32;P<0.001)。
ARC-HBR标准可识别TAVR术后高出血风险患者;ARC-HBR评分升高与患者2年中重度出血事件及死亡率相关。